23种药物与帕金森病之间的关联:一个双样本的门德尔随机化研究
Zhixin Xie1, Haobin Zhou2, Ziyu Qiu3
1Department of Clinical Medicine, The Second Clinical College of Guangzhou Medical University, Guangzhou, Guangdong, China.
Brain and behavior
|September 1, 2023
概括
门德尔的随机化分析表明,酸盐和抗血栓剂可以降低帕金森病 (PD) 的风险. 这一发现为开发PD治疗提供了新的可能性.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 帕金森病 (PD) 是一种流行的神经退行性疾病,疾病修饰的治疗选择有限.
- 探索新的治疗点和药物对于管理PD进展至关重要.
- 门德尔随机化 (MR) 提供了一种可靠的方法来研究药物标和疾病之间的因果关系.
研究的目的:
- 调查23种已批准的药物与患帕金森病的风险之间的潜在因果关系.
- 确定可能影响PD病变的特定药物类别.
- 为了提供证据,重新使用现有的药物用于预防或治疗PD.
主要方法:
- 使用两个样本的门德尔随机化 (MR) 分析.
- 从事全基因组协会研究 (GWAS) 的23种药物的数据来自英国生物银行和芬兰Gen.
- 选择单核酸多态 (SNP) 作为仪器变量,并应用各种统计方法,包括反变量加权 (IVW),加权中位数和MR-Egger,以及灵敏度分析 (MR-PRESSO,科克兰的Q测试).
主要成果:
- 酸盐 (例如,阿司匹林) 显示出与PD风险的统计学上显著的负因果关系 (OR=0.73,P=0.039).
- 抗血栓剂 (例如,华法林,阿司匹林) 也表明与PD风险存在显著的负因果关系 (OR=0.70,P=0.027).
- 对于剩余的21种被调查的药物,没有发现显著的因果关系.
结论:
- 酸盐和抗血栓剂可能在降低帕金森病风险方面发挥保护作用.
- 这些发现表明,在PD的背景下,这些药物类具有潜在的治疗益处.
- 这项研究为未来的药物发现和对帕金森病的重新定位策略开辟了新的途径.
相关概念视频
01:24Parkinson's Disease: Treatment
295
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
295
01:27Combined Effects of Drugs: Synergism
4.0K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
4.0K
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.1K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.1K
01:15Parkinson's Disease: Overview
593
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
593
01:30Combined Effects of Drugs: Antagonism
8.6K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
8.6K
01:29Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K